论文部分内容阅读
目的观察尼可地尔治疗心脏X综合征(CSX)的效果。方法选择2013年1月~12月在本科确诊的CSX的患者45例,随机分为试药组(n=23)及对照组(n=22)。两组患者均给予常规药物治疗,试药组在此基础上给予尼可地尔5 mg,每日3次口服,随访3个月,观察患者胸痛改善情况,复查平板运动试验。结果对照组治疗后比治疗前劳累型心绞痛发作次数降低〔(29.8±5.5)次/月vs.(20.4±4.5)次/月,P<0.05〕,试药组治疗后比治疗前降低〔(31.7±3.4)次/月vs.(19.5±5.1)次/月,P<0.05〕。两组间比较试药组降低更加显著。两组的运动持续总时间、ST段最大压低幅度、运动试验中发作心绞痛人数均有改善,但试药组有更好的作用。结论尼可地尔在心脏CSX患者治疗中能够在基本治疗基础上进一步改善心绞痛症状。
Objective To observe the effect of nicorandil in the treatment of cardiac X syndrome (CSX). Methods Forty-five patients with CSX diagnosed in our department between January 2013 and December 2013 were randomly divided into two groups: experimental group (n = 23) and control group (n = 22). The two groups of patients were given conventional drug treatment, the experimental group on the basis of Nicorandil 5 mg, 3 times daily oral administration, followed up for 3 months to observe the improvement of chest pain in patients with review of treadmill exercise test. Results Compared with the control group, the incidence of exertional angina pectoris was lower than that before treatment [(29.8 ± 5.5) times / month vs. (20.4 ± 4.5) times / month, P < 31.7 ± 3.4) times / month vs. (19.5 ± 5.1) times / month, P <0.05〕. Comparison between the two groups reduced more significant test group. The total duration of exercise, the maximum depression amplitude of ST segment, and the number of patients with angina pectoris during exercise test all improved, but the test group had a better effect. Conclusions Nicorandil can further improve the symptoms of angina pectoris on the basis of basic treatment in the treatment of patients with cardiac CSX.